



**ASX RELEASE**  
**11 February 2015**

**Entitlement Offer - Dispatch of information booklet and entitlement & acceptance form - Tissue Therapies Limited (ASX Code: TIS)**

Tissue Therapies Limited would like to advise that the Rights Issue Information Booklet and Entitlement & Acceptance Form relating to its non-renounceable rights issue announced on 4 February 2015 will be despatched to eligible shareholders today.

**For more information:**

Shareholders can contact Tissue's share registry on 1800 063 366 (within Australia) or +61 1800 063 366 (outside Australia) Monday to Friday.

Tissue Therapies Limited ABN 45 101 955 088 [www.tissuetherapies.com](http://www.tissuetherapies.com)  
Level 19, 179 Turbot Street, Brisbane QLD 4000 Australia  
GPO Box 1596, Brisbane QLD 4001  
telephone +61 7 3334 3900 facsimile +61 7 3334 3999

## What is VitroGro<sup>®</sup> ECM

- VitroGro<sup>®</sup> ECM is a topically applied, biomimetic scaffold, comprising a synthetic extracellular matrix (ECM) protein.
- How it works: VitroGro<sup>®</sup> ECM replaces the degraded matrix of a hard to heal wound. VitroGro<sup>®</sup> ECM binds to a prepared wound bed and provides a physical structure (a scaffold) for cell attachment, which is a primary requirement for subsequent cell functions critical for healing, such as cell proliferation and migration <sup>[1]</sup>.
- An optimal scaffold: One of the characteristics of hard to heal wounds is prolonged inflammation, which damages the native ECM that would normally guide the wound healing process <sup>[1,2,3,4]</sup>. Replacement of this damaged ECM is a beneficial strategy for treating hard to heal wounds <sup>[1]</sup>. VitroGro<sup>®</sup> ECM is ideal as an ECM replacement since its structural and functional elements mimic those present in the ECM at the early stages of normal wound healing.
- Expert health economics modelling indicates that VitroGro<sup>®</sup> ECM offers the opportunity for substantially more cost effective treatment of wounds compared to the current standard of care.

[1] Widgerow AD . Deconstructing the stalled wound. Wounds 2012

[2] Schultz GS. Extracellular Matrix: review of its roles in acute and chronic wounds. World Wide Wounds. 2005

[3] Moor AN. et al. Proteolytic activity in wound fluids and tissues derived from chronic venous leg ulcers. Wound Rep Reg. 2009

[4] International consensus, Acellular matrices for treatment of wounds. Wounds Int. 2010

## About Tissue Therapies Limited

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. Tissue Therapies Limited is commercialising VitroGro<sup>®</sup> ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate. Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges.

More information: [www.tissuetherapies.com](http://www.tissuetherapies.com).